Program
trastuzumab botidotin
Its studies are mostly in Breast Neoplasms · Salivary Gland Neoplasms, led by 2 companies.
Furthest: phase 3, since Apr 26, 20254 company-led studies, 2 open or runningNext primary completion: Nov 30, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical | 32 open or running | phase 3since Apr 26, 2025 | Mar 7, 2022 | Nov 30, 2026phase 3 · NCT06968585 |
| Klus Pharma | 10 open or running | phase 2since Jul 6, 2018 | Jul 6, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2018First study: phase 2 study in Salivary Gland NeoplasmsNew to Klus PharmaKlus Pharma · NCT03602079 · 49 enrolled · United States
- Mar 7, 2022Sichuan Kelun Pharmaceutical's first study: phase 1 study in Breast NeoplasmsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT05311397 · 129 enrolled · China
- Apr 26, 2025Phase 3 study in HER2-positive Breast CancerSichuan Kelun Pharmaceutical · NCT06968585 · 365 enrolled · China
- Dec 3, 2025Phase 2 study in Her 2 Positive Breast CancerSichuan Kelun Pharmaceutical · NCT07299825 · 40 planned · China
Ahead
- Nov 30, 2026Primary completion: phase 3 study in HER2-positive Breast CancerSichuan Kelun Pharmaceutical · NCT06968585
- Sep 20, 2027Primary completion: phase 2 study in Her 2 Positive Breast CancerSichuan Kelun Pharmaceutical · NCT07299825
TargetBeta
ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), ”NCIt, by rule
“Receptor tyrosine-protein kinase erbB-2 binding agent”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07299825Her 2 Positive Breast Cancer · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Sep 20, 2027 | 40 |
| NCT06968585HER2-positive Breast Cancer · China | 3 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Nov 30, 2026 | 365 |
| NCT05311397Breast Neoplasms · China | 1 | Completed | Sichuan Kelun Pharmaceutical | Apr 9, 2026 | 129 |
| NCT03602079Salivary Gland Neoplasms · United States | 2 | Completed | Klus Pharma | Jan 12, 2022 | 49 |
How it is read
Names in the registry
- “A166”, 4 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Salivary Gland Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.